MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

NCT00215566 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2007-05-28

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.

Conditions

  • Irritable Bowel Syndrome With Constipation
  • Irritable Bowel Syndrome

Interventions

DRUG

DDP733

Sponsors & Collaborators

  • Dynogen Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • William Paterson, MD · Hotel Dieu Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215566 on ClinicalTrials.gov